Q-omics provides the consensus-scored FBXO48 profile across patient tissues and cancer cell-line models. FBXO48 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXO48 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, FBXO48 RNA expression shows 20,049 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where FBXO48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO48 survival associations across molecular data types. FBXO48 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO48 RNA expression–survival associations across cancer types. High FBXO48 expression shows unfavorable associations in LGG, MESO and UVM, but favorable associations in KIRC, SCLC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXO48 RNA expression.
This table summarizes FBXO48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO48 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in HNSC, KIRC and BLCA. The HNSC box plot shows higher FBXO48 RNA expression in tumor versus normal tissue (log2 FC = +0.505, t-test p < 0.001).
This table shows molecular features associated with FBXO48 in patient tissues and cancer cell lines. In patient samples, FBXO48 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO48 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
